Active GMP Recombinant Human TNFRSF18 protein, Fc-tagged

• Cat.No.: TNFRSF18-101HG
• Product Overview: GMP Recombinant Human TNFRSF18 protein(NP_683700.1)(368 aa), fused with Fc Tag at the C-terminal, was expressed in HEK293 cell in an animal component free process under cGMP guidelines.

Specification

• Source: HEK293
• Species: Human
• Tag: Fc
• Form: Freeze-dried powder contains Sterile PBS (pH 7.4) with 6% mannitol.
• Bio-activity: The linear range of immobilized Human GITR(Fc tag) at 5ug/mL(100 uL/well) that can bind to Human GITR Ligand(His tag) is 2-100 ng/mL.
• Molecular Mass: Recombinant Human TNFRSF18 protein contains 368 aa. It has a predicted MW of 41.5 kDa.
• Protein length: DNA sequence encoding Human GITR(NCBI Reference Sequence: NP_683700.1) was expressed with Fc tag at the C-terminal.
• Endotoxin: <0.1EU/ug
• Purity: >=95% by SDS-PAGE and HPLC
• Storage: The lyophilized preparation can be stored at 4°C for 24 months, and the dissolved liquid can be stored at -20°C for 6-12 months to avoid repeated freezing and thawing
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens ]
• Official Symbol: TNFRSF18
• Synonyms: AITR; TNFRSF18; CD357
• Gene ID: 8784
• mRNA Refseq: NM_004195
• Protein Refseq: NP_004186
• MIM: 603905
• UniProt ID: Q9Y5U5

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.